CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants,…
<!-- Name:DistributionId Value:8738548 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
CymaBay Therapeutics
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial…
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other…
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™…
Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival NEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY),…
CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label,…
NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative…
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on…
NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and…
CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for…
NEWARK, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other…
CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday,…
NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other…
CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday,…
NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other…